Pretherapy 18 F-FDG PET/CT in Predicting Disease Relapse in Patients With Immunoglobulin G4-Related Disease: A Prospective Study
Korean Journal of Radiology · 2023
DOI: 10.3348/kjr.2022.0576 ↗Kurz gefasst
Fachartikel in der Zeitschrift Korean Journal of Radiology, 2023. Verfasst von Mei-Fang Cheng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Immunoglobulin G4-Related Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Taiwan University Hospital.
Abstract (Originalsprache)
OBJECTIVE: To investigate whether the levels of inflammation detected by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) can predict disease relapse in immunoglobulin G4-related disease (IgG4-RD) patients receiving standard induction steroid therapy. MATERIALS AND METHODS: This prospective study analyzed pretherapy FDG PET/CT images from 48 patients (mean age, 63 ± 12.9 years; 45 males and 3 females) diagnosed with IgG4-RD between September 2008 and February 2018, who subsequently received standard induction steroid therapy as the first-line treatment. Multivariable Cox proportional hazards models were used to identify the potential prognostic factors associated with relapse-free survival (RFS). RESULTS: The median follow-up time for the entire cohort was 1913 days (interquartile range [IQR], 803-2929 days). Relapse occurred in 81.3% (39/48) patients during the follow-up period. The median time to relapse was 210 days (IQR, 140-308 days) after completion of standardized induction steroid therapy. Among the 17 parameters analyzed, Cox proportional hazard analysis identified whole-body total lesion glycolysis (WTLG) > 600 on FDG-PET as an independent risk factor for disease relapse (median RFS, 175 vs. 308 days; adjusted hazard ratio, 2.196 [95% confidence interval: 1.080-4.374]; P = 0.030). CONCLUSION: WTLG on pretherapy FDG PET/CT was the only significant factor associated with RFS in IgG-RD patients receiving standard steroid induction therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
- Institute of Environmental and Occupational Health Sciences, National Taiwan University, Taipei, Taiwan.
- Department of Environmental and Occupational Medicine, National Taiwan University College of Medicine and Hospital, Taipei, Taiwan.
- Department of Nuclear Medicine, Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei, Taiwan.
- School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Department of Internal Medicine, National Taiwan University College of Medicine and Hospital, Taipei, Taiwan. wanghp@ntu.edu.tw.
ORCID-Profile: Mei-Fang Cheng, Yue Leon Guo, Ruoh-Fang Yen, Yen-Wen Wu, Hsiu-Po Wang
Förderung
- National Taiwan University Hospital
Zitieren
APA
Cheng, M. F., Guo, Y. L., Yen, R. F., Wu, Y. W., & Wang, H. P. (2023). Pretherapy 18 F-FDG PET/CT in Predicting Disease Relapse in Patients With Immunoglobulin G4-Related Disease: A Prospective Study. Korean Journal of Radiology. https://doi.org/10.3348/kjr.2022.0576
Vancouver
Cheng MF, Guo YL, Yen RF, Wu YW, Wang HP. Pretherapy 18 F-FDG PET/CT in Predicting Disease Relapse in Patients With Immunoglobulin G4-Related Disease: A Prospective Study. Korean Journal of Radiology. 2023. doi:10.3348/kjr.2022.0576
BibTeX
@article{Cheng2023,
author = {Cheng, Mei-Fang and Guo, Yue Leon and Yen, Ruoh-Fang and Wu, Yen-Wen and Wang, Hsiu-Po},
title = {Pretherapy 18 F-FDG PET/CT in Predicting Disease Relapse in Patients With Immunoglobulin G4-Related Disease: A Prospective Study},
journal = {Korean Journal of Radiology},
year = {2023},
doi = {10.3348/kjr.2022.0576}
}
EUVIMED